ATLANTA — The maker of an expensive drug to prevent premature births slashed the price by more than half on Friday, following an outcry over the high cost and moves by federal regulators to keep a cheap version available.
The drug is still pricey at $690 per weekly injection but it is a drastic reduction from the $1,500 price charged by KV Pharmaceutical Co. when it went on the market last month. The company also announced rebates and other steps to give the drug to needy pregnant women at little or no cost.
The price cut came two days after federal officials said they would not stop specialty pharmacies from continuing to make a generic version that sells for $10 to $20 a dose, as has been done for years.
The company got government approval in February to exclusively sell the drug named Makena (mah-KEE’-nah). But the price stunned doctors who prescribe the drug and private and public insurance plans, including state Medicaid programs, that pay for it. The drug is given to high-risk pregnant women to avoid another early birth.
The pricing controversy exploded after The Associated Press reported on the issue early last month, with some members of Congress calling for a federal investigation.
The Food and Drug Administration, which has no say in drug pricing, took the unusual step of announcing that the special pharmacies could still make the cheap version for individual patients if doctors prescribe it. Typically, those pharmacies aren’t supposed to make versions of licensed drugs, and KV Pharmaceutical had warned them to stop making the preterm birth drug or face enforcement by the FDA.
But on Wednesday, the FDA said that “to support access to this important drug, at this time and under this unique situation,” it would not take action against pharmacies that make the drug.
The agency acted because of the public worries that women won’t be able to afford the drug, federal officials said.
The suburban St. Louis-based KV Pharmaceutical had earlier defended its pricing, saying the company is spending a quarter of a billion dollars on the drug’s development, including $60 million in research.
Chief executive Gregory J. Divis Jr. had said the $1,500 price was justified to avoid the mental and physical disabilities that can result from very premature births. Preemie care can cost an estimated $51,000 in the first year alone, he said.
KV Pharmaceutical officials were not available for an interview on Friday, said a company spokeswoman.
In a statement, Divis acknowledged that prospective buyers of the drug were not happy. He said company officials were cutting the price because they want to make sure all women can get the drug, noting the “budget challenges facing state Medicaid programs and other payers.”
The weekly injection is given for as long as 20 weeks; the price drop cuts the maximum cost of treatment from $30,000 to under $14,000.
KV had earlier announced a patient assistance program to provide the drug to uninsured and low-income women. On Friday, the company announced an expansion of that program, lifting income limits so most women would pay less than $20 per injection. It also offered to cap costs for state Medicaid agencies and health insurance plans.
“They had to respond, they had to bring the price down, because people were so outraged,” said Dr. Kathryn Menard, a University of North Carolina specialist who oversees a state program that has been providing the cheap version of the drug to women at risk for preterm births.
She added that $690 is still pricey, and many obstetricians may prescribe the compounded version.
Sen. Sherrod Brown, D-Ohio, an early and persistent critic of the original price, called the cut “a small step in the right direction,” but said “KV Pharmaceutical is still putting profit over patients.”
The company benefited from nearly $21 million in taxpayer money that was spent on early research on the drug, he noted in a statement.
To read the rest of the article, click on the source link above.Company drops cost of drug to prevent preemie births after FDA says cheap version can be made »